Mount Sinai’s Novel Biomarker Predicts Treatment Outcome in Ovarian Cancer Using Ingenuity Pathway Analysis from QIAGEN

New work from John Martignetti and his lab identified a novel prognostic biomarker indicating whether a patient will respond well or poorly to the standard chemotherapy used for ovarian cancer. The biomarker, which had not previously been linked to ovarian cancer, was found with QIAGEN’s Ingenuity Pathway Analysis (IPA), a leading application for interpreting biological data and modeling complex networks. Now scientists are studying how the biomarker, interferon regulatory factor 1 (IRF1), functions and whether upregulating it might improve ovarian cancer patients’ outcome in the future.